A California company is partnering with Allegheny Health Network to use the company’s trademarked technology to help detect residual cancer in patients after treatment.
Bio-Rad Laboratories Inc. signed a deal with Pittsburgh-based AHN to use the company’s detection system to monitor molecular residual disease in patients who have been treated for a range of solid tumor types.
Residual testing can detect remission and potential relapse of the disease.
“Implementing novel molecular technology in partnership with Bio-Rad will allow us to monitor the response of solid tumors to therapy using routine patient blood samples and will help us achieve proof of concept for Bio-Rad’s platform in detecting molecular residual disease,” William A. LaFramboise, AHN chief genomics technology officer said in a prepared statement.
Bio-Rad Laboratories, which is based in Hercules, develops, manufactures and markets a range of products for the life science research and clinical diagnostic markets. Customers include universities, research institutions, hospitals and others.
Financial details of the deal with AHN were not released.
Kris B. Mamula: kmamula@post-gazette. com





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.